Edgewise Therapeutics, Inc.
EWTXNASDAQHealthcareBiotechnology
Latest quote
$43.92
−$0.0503 · -0.11%
EWTX company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
39
Expensive
Momentum
72
Gaining
Sentiment
67
Bullish
Risk resilience
65
Moderate Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteEdgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Kevin Koch
- Listed since
- Mar 26, 2021
- Employees
- 127
Market position
- Volume
- 258.05K
- 0.19× average
- Average volume
- 1.39M
- Average daily volume
- Market cap
- 4.75B USD
- Beta
- 0.28
- Market reference 1
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -23.85×
- P/B (TTM)
- 10.6×
- P/S (TTM)
- 0×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
Financial health
- Debt / equity
- 0.01×
- Altman Z-score
- 88.07
- Piotroski F-score
- 1 of 9
Earnings
- EPS beat rate
- 64%
- 7 beats, 4 misses, 0 met estimates
- Average EPS surprise
- +1.86%
- 11 comparable reports
- Latest EPS result
- -0.53
- Estimate -0.47 · Miss by 13.32%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$49.45
12.06% upsideRating distribution
11 ratingsEWTX peers
Continue in GoAI
Research EWTXresearch.disclaimer